- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
Dr Hope Rugo: Value Frameworks and Clinical Practice
Hope Rugo, MD, director of the breast oncology clinical trials program at the University of California at San Francisco, discusses guidelines for the treatment of cancer.
Transcript:
In your experience, are value frameworks, such as those developed by NCCN and ASCO, being implemented in clinical practice?
I think value frameworks are being implemented in practice. I think people use guidelines internationally and that they find them very helpful and important.
Interestingly, sometimes people are so concrete with the guidelines [that] it results in more peer-to-peer reviews for patients because they’ll say, “Well you know, you can’t get that drug because it said that they only had 2 lines of therapy there and that patient had 3 lines.” And then we’re like, “Well, it’s not going to make that big of a difference.” Or, they only had 1 and it said the trial was only done in patients that had 2 lines of therapy. You can become very, very concrete in terms of how you interpret those guidelines.
Overall, I think guidelines are important, they give a consensus approach, they take the literature and best practices and provide that information for busy practitioners who are treating many different cancers and provide them essentially with back up.
Also, the guidelines generally provide patient-friendly forms of their guideline information, and that’s incredibly important. We want our patients to be educated as much as possible about what options exist, and it allows patients potentially to participate more in shared decision-making, and to understand when the decisions don’t fit those guidelines.
Q&A With Dr Chelsee Jensen: Navigating FDA Approvals, Challenges in the Biosimilar Landscape
January 14th 2024Chelsee Jensen, PharmD, BCPS, senior pharmacy specialist and pharmaceutical formulary manager at Mayo Clinic, reacts to the biggest FDA approvals of 2023 and how she sees the adalimumab, natalizumab, and tocilizumab spaces playing out.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
IGBA 2023: Dr Monique Mansoura Highlights the Intersection of Geopolitical Issues, Biopharma
February 19th 2023COVID-19 allowed governments to critically examine the biopharma space to increase access to vaccines, but there's still a way to go, according to Monique Mansoura, PhD, MBA, executive director of global health security and biotechnology at the MITRE Corporation, at the International Generic and Biosimilar Medicines Association’s annual meeting.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
